JP7780440B2 - Ｋｖ１．３カリウムシェーカーチャネル遮断薬としてのアリール複素二環式化合物 - Google Patents

Ｋｖ１．３カリウムシェーカーチャネル遮断薬としてのアリール複素二環式化合物

Info

Publication number
JP7780440B2
JP7780440B2 JP2022546592A JP2022546592A JP7780440B2 JP 7780440 B2 JP7780440 B2 JP 7780440B2 JP 2022546592 A JP2022546592 A JP 2022546592A JP 2022546592 A JP2022546592 A JP 2022546592A JP 7780440 B2 JP7780440 B2 JP 7780440B2
Authority
JP
Japan
Prior art keywords
alkyl
compound
mmol
dichloro
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022546592A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022551199A (ja
JP2022551199A5 (https=
Inventor
ジョルダネット，ファブリツィオ
エステルガールド イェンセン，モルテン
ジョギーニ，ビシュワナス
ジョン スノウ，ロジャー
Original Assignee
ディー．イー．ショウ リサーチ，エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ディー．イー．ショウ リサーチ，エルエルシー filed Critical ディー．イー．ショウ リサーチ，エルエルシー
Publication of JP2022551199A publication Critical patent/JP2022551199A/ja
Publication of JP2022551199A5 publication Critical patent/JP2022551199A5/ja
Application granted granted Critical
Publication of JP7780440B2 publication Critical patent/JP7780440B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2022546592A 2019-10-07 2020-10-06 Ｋｖ１．３カリウムシェーカーチャネル遮断薬としてのアリール複素二環式化合物 Active JP7780440B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962911648P 2019-10-07 2019-10-07
US62/911,648 2019-10-07
PCT/US2020/054393 WO2021071832A1 (en) 2019-10-07 2020-10-06 Aryl heterobicyclic compounds as kv1.3 potassium shaker channel blockers

Publications (3)

Publication Number Publication Date
JP2022551199A JP2022551199A (ja) 2022-12-07
JP2022551199A5 JP2022551199A5 (https=) 2024-05-20
JP7780440B2 true JP7780440B2 (ja) 2025-12-04

Family

ID=75438321

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022546592A Active JP7780440B2 (ja) 2019-10-07 2020-10-06 Ｋｖ１．３カリウムシェーカーチャネル遮断薬としてのアリール複素二環式化合物

Country Status (10)

Country Link
US (1) US20230049231A1 (https=)
EP (1) EP4041405A4 (https=)
JP (1) JP7780440B2 (https=)
KR (1) KR20220079878A (https=)
AU (1) AU2020362118A1 (https=)
BR (1) BR112022006292A2 (https=)
CA (1) CA3157020A1 (https=)
IL (1) IL291866A (https=)
MX (1) MX2022004178A (https=)
WO (1) WO2021071832A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023003841A (es) 2020-10-06 2023-06-23 De Shaw Res Llc Compuestos lactámicos como bloqueadores del canal agitador de potasio kv1.3.
TW202521512A (zh) 2023-07-31 2025-06-01 美商美國禮來大藥廠 Kv1.3鉀shaker通道阻斷劑之固體形式及其使用方法
WO2025161144A1 (zh) * 2024-01-29 2025-08-07 上海深势唯思科技有限责任公司 芳基杂环类Kv1.3抑制剂及其制备方法和用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004511516A (ja) 2000-10-17 2004-04-15 ワイス 膀胱の機能を調節する方法
JP2006512378A (ja) 2002-12-23 2006-04-13 ブリストル−マイヤーズ　スクイブ　カンパニー ３−置換−４−アリールキノリン−２−オン誘導体のアトロプ異性体
JP2007506749A (ja) 2003-09-23 2007-03-22 メルク　エンド　カムパニー　インコーポレーテッド イソキノリンカリウムチャネル阻害剤
WO2011073273A1 (en) 2009-12-16 2011-06-23 Evotec Ag Benzoxazine aryl sulfonamide derivatives as kv1.3 modulators

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
JP4377231B2 (ja) * 2001-11-05 2009-12-02 大日本住友製薬株式会社 新規なカルバペネム化合物
US7538110B2 (en) * 2005-10-27 2009-05-26 Adolor Corporation Opioid antagonists
TWI370130B (en) * 2005-11-24 2012-08-11 Eisai R&D Man Co Ltd Two cyclic cinnamide compound

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004511516A (ja) 2000-10-17 2004-04-15 ワイス 膀胱の機能を調節する方法
JP2006512378A (ja) 2002-12-23 2006-04-13 ブリストル−マイヤーズ　スクイブ　カンパニー ３−置換−４−アリールキノリン−２−オン誘導体のアトロプ異性体
JP2007506749A (ja) 2003-09-23 2007-03-22 メルク　エンド　カムパニー　インコーポレーテッド イソキノリンカリウムチャネル阻害剤
WO2011073273A1 (en) 2009-12-16 2011-06-23 Evotec Ag Benzoxazine aryl sulfonamide derivatives as kv1.3 modulators

Also Published As

Publication number Publication date
KR20220079878A (ko) 2022-06-14
JP2022551199A (ja) 2022-12-07
EP4041405A4 (en) 2023-10-18
US20230049231A1 (en) 2023-02-16
WO2021071832A1 (en) 2021-04-15
AU2020362118A1 (en) 2022-04-21
IL291866A (en) 2022-06-01
MX2022004178A (es) 2022-06-16
CA3157020A1 (en) 2021-04-15
BR112022006292A2 (pt) 2022-06-28
CN114828963A (zh) 2022-07-29
EP4041405A1 (en) 2022-08-17

Similar Documents

Publication Publication Date Title
JP2025186255A (ja) Ｋｖ１．３カリウムシェーカーチャネル遮断薬としてのアリール複素環式化合物
JP7763271B2 (ja) Ｋｖ１．３カリウムシェーカーチャネル遮断剤としてのスピロインドリノン化合物
JP2025020196A (ja) Ｋｖ１．３カリウムシェーカーチャネル遮断薬としてのアリールメチレン複素環式化合物
JP7780439B2 (ja) Ｋｖ１．３カリウムシェーカーチャネル遮断薬としてのアリール複素二環式化合物
WO2022076285A1 (en) LACTAM COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS
JP7780440B2 (ja) Ｋｖ１．３カリウムシェーカーチャネル遮断薬としてのアリール複素二環式化合物
JP2025131590A (ja) Ｋｖ１．３カリウムシェーカーチャネル遮断剤としてのアリール複素環化合物
CN114828963B (zh) 作为Kv1.3钾SHAKER通道阻滞剂的芳基杂二环化合物
EA046803B1 (ru) АРИЛЬНЫЕ ГЕТЕРОБИЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ КАК БЛОКАТОРЫ КАЛИЕВОГО КАНАЛА Kv1.3 ТИПА SHAKER

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231005

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231005

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240508

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240930

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241008

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241226

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250303

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250407

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250624

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250919

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251111

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251121

R150 Certificate of patent or registration of utility model

Ref document number: 7780440

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150